Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Items 401–500 of 1,001
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
Choi, W., Woo, G. H., Kwon, T., & Jeon, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199715 · Cited by 130
“In a landmark study, treating T2DM patients with an IL-1 receptor antagonist (anakinra) for several months improved glycemic control and β -cell secretory function [80].”
Islet inflammation: a unifying target for diabetes treatment?
Imai, Y., Dobrian, A. D., Morris, M. A., & Nadler, J. L. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.01.007 · Cited by 119
IL-1β Receptor Antagonist Reduces Inflammation in Hemodialysis Patients
Hung, A. M., Ellis, C. D., Shintani, A., Booker, C., & Ikizler, T. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010070760 · Cited by 117
Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes
Biason-Lauber, A., Böni-Schnetzler, M., Hubbard, B. P., Bouzakri, K., Brunner, A., Cavelti-Weder, C., Keller, C., Meyer-Böni, M., Meier, D. T., Brorsson, C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.001 · Cited by 116
Self-citationRole of Caspase-1 in the Pathogenesis of Inflammatory-Associated Chronic Noncommunicable Diseases
Molla, M. D., Akalu, Y., Geto, Z., Dagnew, B., Ayelign, B., & Shibabaw, T. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s277457 · Cited by 131
Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus
Mandrup-Poulsen, T., Seifert, B., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071324 · Cited by 119
Self-citationSampson, U. K., Linton, M. F., & Fazio, S. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283470359 · Cited by 116
Inflammasomes and Metabolic Disorders: Old Genes in Modern Diseases
Robbins, G. R., Wen, H., & Ting, J. P.-Y. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.029 · Cited by 115
“These findings highlight IL-1β as a potential therapeutic target for the treatment of T2D and small-scale studies employing recombinant IL-1 receptor antagonist (IL-1Ra) provide encouraging data in the treatment of T2D (Larsen et al., 2007).”
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101549 · Cited by 124
Therapeutic Approaches to Target Inflammation in Type 2 Diabetes
Goldfine, A. B., Fonseca, V., & Shoelson, S. E. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.148833 · Cited by 116
Inflammasomes as molecular mediators of inflammation and cancer: Potential role in melanoma
Dunn, J. H., Ellis, L. Z., & Fujita, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.001 · Cited by 124
Vinuesa, Á., Pomilio, C. J., Gregosa, A., Bentivegna, M., Presa, J., Bellotto, M., Saravia, F., & Beauquis, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653651 · Cited by 122
IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth chronicity
Zaiss, M. M., Maslowski, K. M., Mosconi, I., Guenat, N., Marsland, B. J., & Harris, N. L. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003531 · Cited by 116
Kono, T., Ahn, G., Moss, D. R., Gann, L., Zarain-Herzberg, A., Nishiki, Y., Fueger, P. T., Ogihara, T., & Evans-Molina, C. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1181 · Cited by 118
Ippagunta, S. K., Malireddi, R. K. S., Shaw, P. J., Neale, G. A., Walle, L. V., Green, D. R., Fukui, Y., Lamkanfi, M., & Kanneganti, T.-D. (2011) · Nature Immunology · doi:10.1038/ni.2095 · Cited by 113
Lewis, E. C., Blaabjerg, L., Størling, J., Rønn, S. G., Mascagni, P., Dinarello, C. A., & Mandrup-Poulsen, T. R. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00152 · Cited by 117
Self-citationGuo, J., Gu, N.-L., Chen, J., Shi, T., Zhou, Y., Rong, Y., Zhou, T., Yang, W., Cui, X., & Chen, W. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1063-z · Cited by 124
Ryan, K. K., Woods, S. C., & Seeley, R. J. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.013 · Cited by 113
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
Fürst, D. E., Keystone, E. C., Kirkham, B., Fleischmann, R., Mease, P. J., Fc, B., Smolen, J. S., Kalden, J. R., Burmester, G. R., Braun, J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.100834 · Cited by 129
Origins and diversity of macrophages in health and disease
Sreejit, G., Fleetwood, A. J., Murphy, A. J., & Nagareddy, P. R. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1222 · Cited by 126
Liu, P., Zhang, Z., & Yao, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.603416 · Cited by 120
“Increased IL-1b has emerged as an essential factor for predicting the occurrence of T2DM.”
BackgroundInfluentialWang, X., Jia, S., Geoffrey, R., Alemzadeh, R., Ghosh, S., & Hessner, M. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1929 · Cited by 110
Inflammatory Signaling and Brown Fat Activity
Omran, F., & Christian, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00156 · Cited by 120
Mauer, J., Chaurasia, B., Plum, L., Quast, T., Hampel, B., Blüher, M., Kolanus, W., Kahn, C. R., & Brüning, J. C. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000938 · Cited by 110
Rekedal, L., Massarotti, E. M., Garg, R., Bhatia, R., Gleeson, T., Lü, B., & Solomon, D. H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27703 · Cited by 119
“Anakinra – an IL-1 receptor antagonist FDA approved for the treatment of RA – was examined as a therapy for DM, and associated with significantly lower glycated hemoglobin (HbA1c) [20].”
BackgroundCytokine Dysregulation in Chronic Kidney Disease: How Can We Treat It?
Carrero, J. J., Yılmaz, M. İ., Lindholm, B., & Stenvinkel, P. (2008) · Blood Purification · doi:10.1159/000126926 · Cited by 110
‘Giving and taking’: endothelial and β-cells in the islets of Langerhans
Eberhard, D., Kragl, M., & Lammert, E. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.03.003 · Cited by 121
RNAi-based therapeutic strategies for metabolic disease
Czech, M., Aouadi, M., & Tesz, G. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.57 · Cited by 118
Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade
Ablamunits, V., Henegariu, O., Hansen, J. B., Opare-Addo, L., Preston-Hurlburt, P., Santamaria, P., Mandrup-Poulsen, T., & Herold, K. C. (2012) · Diabetes · doi:10.2337/db11-1033 · Cited by 107
Self-citationEstrada, E. J., Valacchi, F., Nicora, E., Brieva, S., Esteve, C., Echevarria, L., Froud, T., Bernetti, K., Messinger, S., Velazquez, O. C., et al. (2008) · Cell Transplantation · doi:10.3727/096368908787648119 · Cited by 111
Statins are diabetogenic – Myth or reality?
Sattar, N. A., & Taskinen, M. (2012) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2012.06.001 · Cited by 117
Adiposity‐related inflammation: Effects of pregnancy
Friis, C. M., Paasche Roland, M. C., Godang, K., Ueland, T., Tanbo, T., Bollerslev, J., & Henriksen, T. (2013) · Obesity · doi:10.1002/oby.20120 · Cited by 104
Metabolic Inflammation-Differential Modulation by Dietary Constituents
Lyons, C., Kennedy, E., & Roche, H. (2016) · Nutrients · doi:10.3390/nu8050247 · Cited by 104
Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy
Kelly, A., De Leon, D. D., Sheikh, S., Camburn, D., Kubrak, C., Peleckis, A. J., Stefanovski, D., Hadjiliadis, D., Rickels, M. R., & Rubenstein, R. C. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1018oc · Cited by 104
Obesity and chronic inflammation crosslinking
Artemniak-Wojtowicz, D., Kucharská, A., & Pyrżak, B. (2021) · Central European Journal of Immunology · doi:10.5114/ceji.2020.103418 · Cited by 113
Danger Signaling in Atherosclerosis
Zimmer, S., Grebe, A., & Latz, E. (2015) · Circulation Research · doi:10.1161/circresaha.116.301135 · Cited by 101
Lopalco, G., Cantarini, L., Vitale, A., Iannone, F., Anelli, M. G., Andreozzi, L., Lapadula, G., Galeazzi, M., & Rigante, D. (2015) · Mediators of Inflammation · doi:10.1155/2015/194864 · Cited by 110
Interleukin-1 as a mediator of fatigue in disease: a narrative review
Roerink, M. E., van der Schaaf, M. E., Dinarello, C. A., Knoop, H., & van der Meer, J. W. M. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0796-7 · Cited by 102
Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment
Pellegrini, V., Grotta, R. L., Carreras, F., Giuliani, A., Sabbatinelli, J., Olivieri, F., Berra, C., Ceriello, A., & Prattichizzo, F. (2024) · Cells · doi:10.3390/cells13191662 · Cited by 117
Action LADA Study Group, Pham, M. N., Hawa, M. I., Pfleger, C., Roden, M., Schernthaner, G., Pozzilli, P., Buzzetti, R., Scherbaum, W. A., Seißler, J., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2088-6 · Cited by 113
“Treatment with IL-1RA in longterm type 2 diabetes patients has shown to improve HbA1c and to increase endogenous insulin secretion [ 17 ].”
BackgroundAnti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes
Kuryłowicz, A., & Koźniewski, K. (2020) · Molecules · doi:10.3390/molecules25092224 · Cited by 99
“glucose control and peripheral insulin sensitivity (see below) [78].”
BackgroundRamadan, J. W., Steiner, S. R., O’Neill, C. M., & Nunemaker, C. S. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.08.005 · Cited by 116
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 112
The Nlrp3 inflammasome as a “rising star” in studies of normal and malignant hematopoiesis
Ratajczak, M. Z., Bujko, K., Cymer, M., Thapa, A., Adamiak, M., Ratajczak, J., Abdel-Latif, A. K., & Kucia, M. (2020) · Leukemia · doi:10.1038/s41375-020-0827-8 · Cited by 102
Carolan, E., Hogan, A. E., Corrigan, M. A., Gaotswe, G., O’Connell, J., Foley, N. H., O'Neill, L. A. J., Cody, D., & O'Shea, D. B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3529 · Cited by 103
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Benetti, E., Mastrocola, R., Vitarelli, G., Cutrìn, J. C., Nigro, D., Chiazza, F., Mayoux, E., Collino, M., & Fantozzi, R. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235069 · Cited by 104
Chemerin regulation and role in host defense.
Zabel, B. A., Kwitniewski, M., Banaś, M., Zabieglo, K., Murzyn, K., & Cichy, J. (2014) · Europe PMC (PubMed Central) · Cited by 121
Widenmaier, S. B., Ao, Z., Kim, S.-J., Warnock, G., & McIntosh, C. H. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.060178 · Cited by 96
Macrophages, fat, and the emergence of immunometabolism
Ferrante, A. W. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73658 · Cited by 103
Alam, I., Ng, T. P., & Larbi, A. (2012) · Mediators of Inflammation · doi:10.1155/2012/456456 · Cited by 117
Multiple benefits of targeting inflammation in the treatment of type 2 diabetes
Donath, M. Y. (2016) · Diabetologia · doi:10.1007/s00125-016-3873-z · Cited by 108
Self-citationType 2 diabetes – An autoinflammatory disease driven by metabolic stress
Gonzalez, L. L., Garrie, K., & Turner, M. D. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.034 · Cited by 110
Ghanbari, M., Maragheh, S. M., Aghazadeh, A., Mehrjuyan, S. R., Hussen, B. M., Shadbad, M. A., Dastmalchi, N., & Safaralizadeh, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107765 · Cited by 107
Adipose tissue inflammation in glucose metabolism
Kammoun, H. L., Kraakman, M. J., & Febbraio, M. A. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9274-4 · Cited by 111
Jagannathan, M., Hasturk, H., Liang, Y., Shin, H., Hetzel, J. T., Kantarci, A., Rubin, D., McDonnell, M. E., Van Dyke, T. E., Ganley-Leal, L. M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901517 · Cited by 99
Suppression of NLRP3 inflammasome by γ-tocotrienol ameliorates type 2 diabetes
Kim, Y., Wang, W., Okla, M., Kang, I., Moreau, R., & Chung, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m062828 · Cited by 98
Microvesicles and exosomes in metabolic diseases and inflammation
Dini, L., Tacconi, S., Carata, E., Tata, A. M., Vergallo, C., & Panzarini, E. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.12.008 · Cited by 103
Kamata, K., Mizukami, H., Inaba, W., Tsuboi, K., Tateishi, Y., Yoshida, T., & Yagihashi, S. (2014) · Amyloid · doi:10.3109/13506129.2014.937857 · Cited by 97
Kalliolias, G. D., & C Liossis, S.-N. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.349 · Cited by 102
Straub, R. H. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4688 · Cited by 109
Macrophages, cytokines and β-cell death in Type 2 diabetes
Ehses, J. A., Böni-Schnetzler, M., Faulenbach, M., & Donath, M. Y. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360340 · Cited by 92
Self-citationInsulin Resistance and Protein Energy Metabolism in Patients with Advanced Chronic Kidney Disease
Siew, E. D., & Ikizler, T. A. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00763.x · Cited by 99
Obesity and the gut microbiome: Striving for causality
Harley, I. T. W., & Karp, C. L. (2012) · Molecular Metabolism · doi:10.1016/j.molmet.2012.07.002 · Cited by 96
Regulation of inflammasome activity
Guarda, G., & So, A. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03283.x · Cited by 95
The implication of proinflammatory cytokines in type 2 diabetes
Guest, C. (2008) · Frontiers in Bioscience · doi:10.2741/3074 · Cited by 98
Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines
Schmitz, M. L., Weber, A., Roxlau, T., Gaestel, M., & Kracht, M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.06.019 · Cited by 110
Getting away from glucose: fanning the flames of obesity-induced inflammation
Shoelson, S. E., & Goldfine, A. B. (2009) · Nature Medicine · doi:10.1038/nm0409-373 · Cited by 98
Mielke, L. A., Elkins, K. L., Wei, L., Starr, R., Tsichlis, P. N., O'Shea, J. J., & Watford, W. T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901336 · Cited by 98
Metabolic stress, IAPP and islet amyloid
Montane, J., Klimek‐Abercrombie, A., Potter, K. J., Westwell‐Roper, C., & Bruce Verchere, C. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01657.x · Cited by 98
Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity
Oishi, Y., & Manabe, I. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00064 · Cited by 101
“Accordingly, that study as well as others (145, 146) support the notion that targeting inflammatory signals is an effective and feasible strategy against cardiometabolic disease.”
BackgroundPancreatic islet inflammation in type 2 diabetes: From α and β cell compensation to dysfunction
Ehses, J. A., Ellingsgaard, H., Böni-Schnetzler, M., & Donath, M. Y. (2009) · Archives of Physiology and Biochemistry · doi:10.1080/13813450903025879 · Cited by 97
Self-citationFuentes‐Antrás, J., Ioan, A.-M., Tuñón, J., Egido, J., & Lorenzo, Ó. (2014) · International Journal of Endocrinology · doi:10.1155/2014/847827 · Cited by 103
Adaptive immune cells in calcific aortic valve disease
Raddatz, M. A., Madhur, M. S., & Merryman, W. D. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00100.2019 · Cited by 91
“Similarly, diabetes is defined by an IL-1-dependent increase in acute phase reactants (43, 86), and atherosclerosis is associated with an increase in inflammatory markers (62, 97).”
BackgroundStukenbrock, H., Mußmann, R., Geese, M., Ferandin, Y., Lozach, O., Lemcke, T., Kegel, S., Lomow, A., Burk, U., Dohrmann, C. E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701582f · Cited by 101
Goldbach‐Mansky, R. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05159.x · Cited by 96
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Waldron-Lynch, F., & Herold, K. C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3402 · Cited by 106
“Consistent with findings from models of type 1 diabetes, data from this trial suggested that direct protective effects on β-cells, rather than insulin resistance (also believed to be mediated through IL-1β), accounted for the improvement in metabolic contro”
ResultAkash, M. S. H., Rehman, K., & Chen, S. (2013) · Current Diabetes Reviews · doi:10.2174/15733998113099990069 · Cited by 97
“Data were obtained from Ostenson and Efendic 2007 [18], Larsen et al 2007 [19], Ehses et al 2009 [20], Edholm”
MethodInflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging
Barbu, E., Popescu, M.-R., Popescu, A.-C., & Balanescu, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020963 · Cited by 107
McCall, M., Pawlick, R., Kin, T., & Shapiro, A. M. J. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03796.x · Cited by 93
Aye, I. L. M. H., Jansson, T., & Powell, T. L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.013 · Cited by 95
Xiang, A. H., Kawakubo, M., Trigo, E., Kjos, S. L., & Buchanan, T. A. (2010) · Diabetes Care · doi:10.2337/dc09-1493 · Cited by 95
Activation of inflammasomes in adipose tissue of women with gestational diabetes
Lappas, M. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.011 · Cited by 99
Owyang, A. M., Maedler, K., Gross, L., Yin, J., Esposito, L., Shu, L., Jadhav, J., Domsgen, E., Bergemann, J., Lee, S., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1124 · Cited by 95
The NLRP3 inflammasome: Role in metabolic disorders and regulation by metabolic pathways
Jiang, D., Chen, S., Sun, R., Zhang, X., & Wang, D. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.034 · Cited by 102
Hyperglycemia induces mixed M1/M2 cytokine profile in primary human monocyte-derived macrophages
Moganti, K., Li, F., Schmuttermaier, C., Riemann, S., Klüter, H., Gratchev, A. N., Harmsen, M. C., & Kzhyshkowska, J. G. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.07.006 · Cited by 102
Popovic, M., Sartorius, G. A., & Christ‐Crain, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00737-4 · Cited by 103
Inflammasomes and Pyroptosis of Liver Cells in Liver Fibrosis
Gan, C., Cai, Q., Tang, C., & Gao, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896473 · Cited by 96
Ogata, A., Morishima, A., Hirano, T., Hishitani, Y., Hagihara, K., Shima, Y., Narazaki, M., & Tanaka, T. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.132845 · Cited by 100
Humoral Sleep Regulation; Interleukin-1 and Tumor Necrosis Factor
Jewett, K. A., & Krueger, J. M. (2012) · Vitamins & Hormones · doi:10.1016/b978-0-12-394623-2.00013-5 · Cited by 93
β-Cell deterioration during diabetes: what’s in the gun?
Robertson, R. P. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.05.004 · Cited by 93
Herder, C., Baumert, J. J., Zierer, A., Roden, M., Meisinger, C., Karakas, M., Chambless, L. E., Rathmann, W., Peters, A., Köenig, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019852 · Cited by 100
Impaired macrophage autophagy induces systemic insulin resistance in obesity
Kang, Y.-H., Cho, M.-H., Kim, J.-Y., Kwon, M.-S., Peak, J.-J., Kang, S.-W., Yoon, S.-Y., & Song, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9590 · Cited by 91
The NLRP3 inflammasome regulates adipose tissue metabolism
Barra, N. G., Henriksbo, B. D., Anhê, F. F., & Schertzer, J. D. (2020) · Biochemical Journal · doi:10.1042/bcj20190472 · Cited by 93
Marques-Vidal, P. M., Bastardot, F., von Känel, R., Paccaud, F. M., Preisig, M., Waeber, G., & Vollenweider, P. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04384.x · Cited by 103
Antonelli, A., Fallahi, P., Ferrari, S., Pupilli, C., d’Annunzio, G., Lorini, R., Vanelli, M. I., & Ferrannini, E. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02577.x · Cited by 93
IL‐1 family in breast cancer: Potential interplay with leptin and other adipocytokines
Perrier, S., Caldefie-Chézet, F., & Vasson, M.-P. (2009) · FEBS Letters · doi:10.1016/j.febslet.2008.12.030 · Cited by 92
Association of Subclinical Inflammation With Polyneuropathy in the Older Population
Herder, C., Bongaerts, B. W. C., Rathmann, W., Heier, M., Kowall, B., Koenig, W., Thorand, B., Roden, M., Meisinger, C., & Ziegler, D. (2013) · Diabetes Care · doi:10.2337/dc13-0382 · Cited by 88
Role of pancreatic β ‐cell death and inflammation in diabetes
Quan, W., Jo, E., & Lee, M. ‐. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12153 · Cited by 103
Diabetes mellitus: new challenges and innovative therapies
Sena, C. M., Bento, C. F., Pereira, P., & Seiça, R. M. F. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0010-9 · Cited by 105
The inflammasome: in memory of Dr. Jurg Tschopp
Dagenais, M., Skeldon, A. M., & Saleh, M. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.159 · Cited by 105
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.